Nvidia, the U.S.-based AI chip giant, has unveiled Evo 2, the most advanced artificial intelligence system dedicated to biomolecular science. Built-in collaboration with Stanford University and the nonprofit Arc Institute, Evo 2 is set to redefine genetic research, accelerating breakthroughs in medicine and biotechnology.
AI Meets Genomics
Powered by Nvidia DGX Cloud on Amazon Web Services (AWS), Evo 2 is designed to decode the complexities of DNA, RNA, and proteins across a vast spectrum of species. With a dataset of nearly 9 trillion nucleotides—the fundamental units of DNA and RNA—this AI model is poised to revolutionize biological research. Its capabilities extend to predicting protein structures, identifying novel molecules for healthcare and industrial applications, and analyzing the effects of genetic mutations.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
Evo 2 is now the largest publicly available AI model for genomic data, offering scientists an unprecedented tool for biological discovery. Researchers can leverage Nvidia’s NIM microservice to generate biological sequences and fine-tune the model using their proprietary datasets via the open-source Nvidia BioNeMo Framework.
Game-Changing Potential
“Evo 2 represents a major milestone for generative genomics,” said Patrick Hsu, cofounder of Arc Institute and assistant professor of bioengineering at UC Berkeley. “By deepening our understanding of life’s fundamental building blocks, we can unlock new possibilities in healthcare and environmental science that were once unimaginable.”
Brian Hie, assistant professor of chemical engineering at Stanford and faculty fellow at the Dieter Schwarz Foundation Stanford Data Science, echoed this sentiment: “With Evo 2, complex biological design becomes more accessible, allowing researchers to develop groundbreaking innovations in a fraction of the time.”
Market Reaction
Despite the breakthrough, Nvidia’s stock dipped 0.2% in after-hours trading on Wednesday, settling at $139 per share, with a market capitalization of $3.4 trillion. However, as AI-driven biotech advances continue to gain momentum, Nvidia’s role in shaping the future of medicine and genomics remains stronger than ever.
